Bioxcel Therapeutics Stock Performance
| BTAI Stock | USD 2.33 0.03 1.27% |
The firm shows a Beta (market volatility) of 1.6, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioXcel Therapeutics will likely underperform. At this point, BioXcel Therapeutics has a negative expected return of -0.47%. Please make sure to confirm BioXcel Therapeutics' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if BioXcel Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days BioXcel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (1.27) | Five Day Return (1.69) | Year To Date Return (62.84) | Ten Year Return (98.68) | All Time Return (98.68) |
Last Split Factor 1:16 | Last Split Date 2025-02-10 |
1 | Acquisition by Mack David J. of 27089 shares of BioXcel Therapeutics subject to Rule 16b-3 | 12/31/2024 |
2 | Insider Trading | 01/15/2025 |
3 | BioXcel Therapeutics Appoints Dr. Rajiv Patni to Board of Directors | 01/17/2025 |
4 | BioXcel Therapeutics Announces 14 Million Registered Direct Offering | 03/03/2025 |
5 | BioXcel Therapeutics Announces Closing of 14 Million Registered Direct Offering | 03/04/2025 |
6 | ScPharmaceuticals, Inc. Expected to Beat Earnings Estimates Should You Buy | 03/05/2025 |
7 | Disposition of 2610 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3 | 03/07/2025 |
8 | BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar... | 03/11/2025 |
9 | Disposition of 217 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3 | 03/14/2025 |
10 | BioXcel Therapeutics Upgraded by RODMANRENSHAW to Strong-Buy Rating | 03/21/2025 |
| Begin Period Cash Flow | 193.7 M |
BioXcel |
BioXcel Therapeutics Relative Risk vs. Return Landscape
If you would invest 562.00 in BioXcel Therapeutics on December 24, 2024 and sell it today you would lose (329.00) from holding BioXcel Therapeutics or give up 58.54% of portfolio value over 90 days. BioXcel Therapeutics is currently does not generate positive expected returns and assumes 14.9648% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioXcel, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioXcel Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioXcel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioXcel Therapeutics, and traders can use it to determine the average amount a BioXcel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0317
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BTAI |
Estimated Market Risk
| 14.96 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioXcel Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioXcel Therapeutics by adding BioXcel Therapeutics to a well-diversified portfolio.
BioXcel Therapeutics Fundamentals Growth
BioXcel Stock prices reflect investors' perceptions of the future prospects and financial health of BioXcel Therapeutics, and BioXcel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioXcel Stock performance.
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (64.21) % | ||||
| Current Valuation | 72.63 M | ||||
| Shares Outstanding | 3.39 M | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 3.47 X | ||||
| Revenue | 1.38 M | ||||
| Gross Profit | 251 K | ||||
| EBITDA | (165.42 M) | ||||
| Net Income | (179.05 M) | ||||
| Cash And Equivalents | 233.45 M | ||||
| Cash Per Share | 8.33 X | ||||
| Total Debt | 101.38 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 12.25 X | ||||
| Book Value Per Share | (32.27) X | ||||
| Cash Flow From Operations | (155.01 M) | ||||
| Earnings Per Share | (32.64) X | ||||
| Market Capitalization | 7.91 M | ||||
| Total Asset | 73.7 M | ||||
| Retained Earnings | (590.6 M) | ||||
| Working Capital | 44.88 M | ||||
| Current Asset | 609.37 K | ||||
| Current Liabilities | 1.67 M | ||||
About BioXcel Therapeutics Performance
By evaluating BioXcel Therapeutics' fundamental ratios, stakeholders can gain valuable insights into BioXcel Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioXcel Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioXcel Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 663.27 | 630.11 | |
| Return On Tangible Assets | (2.19) | (2.30) | |
| Return On Capital Employed | (4.25) | (4.04) | |
| Return On Assets | (2.19) | (2.30) | |
| Return On Equity | 3.64 | 3.83 |
Things to note about BioXcel Therapeutics performance evaluation
Checking the ongoing alerts about BioXcel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioXcel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioXcel Therapeutics generated a negative expected return over the last 90 days | |
| BioXcel Therapeutics has high historical volatility and very poor performance | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 251 K. | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: BioXcel Therapeutics Upgraded by RODMANRENSHAW to Strong-Buy Rating |
- Analyzing BioXcel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioXcel Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining BioXcel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioXcel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioXcel Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioXcel Therapeutics' stock. These opinions can provide insight into BioXcel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |